CTI's Pixuvri Strategy After FDA Rejection: Expanded Access, Combo Trial

Cell Therapeutics plans to pursue an expanded access program for its non-Hodgkin's lymphoma drug Pixuvri (pixantrone) while it conducts a new combination therapy trial to satisfy concerns raised in FDA's April 9 "complete response" letter